Document is current

Article History

Received: 5 April 2024

Accepted: 20 June 2024

First Online: 8 July 2024

Declarations

:

: All methods were carried out in accordance with relevant guidelines and regulations. The animal procedures were approved by Animal Ethics Committees: the microPET and ex vivo biodistribution protocols were approved by the Ist Local Animal Ethics Committee in Warsaw (authorization 069/2016, approval date 15 June 2016, with further changes 445/2017 and authorization 400/2017, approval date 21 November 2017, respectively), the toxicity studies were approved by Local Animal Ethical Committee in Katowice, Poland (authorizations 45/2018 and 107/2018, approval dates 16 May and 16 November 2018) and pharmacokinetic profile with SYN2 was carried out based on authorization no. PROEX 211/10 (approval date 12.09.2019) issued by Spanish General Director of Agriculture, Livestock and Food. The study was carried out in compliance with the ARRIVE guidelines.

: No human participants or human data was involved in the study. Hepatocytes of human (50-donor, Lot no. HQE, X008005), dog (Male Beagle dog, Lot no. UXH, M00205) and rat (Male Wistar rat, Lot no. ATI, M00025) were purchased from BioreclamationIVT (Brussels, Belgium).

: Not applicable.

: J.K. and M.D. are advisors and received the consultant honoraria from Synektik SA. The other authors have no relevant financial or non-financial interests to disclose.